Key facts
- Decade ( Biotechnology)’s last known valuation is $17.0M (Aug 2025).
- It has raised $7.8M; the latest was Seed Round ($7.8M) in Aug 2025.
- Notable investors include 500 Global.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Decade ( Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for Decade ( Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Decade ( Biotechnology)
Developer of targeted cancer therapies designed to address unique molecular signatures in tumors. The company uses artificial intelligence, high-throughput data analysis, and molecular profiling, enabling oncology providers and researchers to deliver more precise and individualized treatments for cancer patients.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- decade.bio/
- Ownership
- Privately Held (backing)
Decade ( Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Decade ( Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Decade ( Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.